linjc16/ctgov huggingface dataset:
Satisfaction With an In-house Developed Nasal Foreign Body Removal Manikin

Study Overview
=================
Brief Summary
-----------------
To overcome the issues regarding training in real persons, using a simulated manikin instead of an actual patient or simulated patient is another option with consideration to the training able to be held at any time periods and no issues about minor or serious complications needed to be concerned with. The aim of this study is to devise a low-cost manikin with a specific design to serve all possible needs of end users but still keep its function as necessary for training.

Official Title
-----------------
Satisfaction With an In-house Developed Nasal Foreign Body Removal Manikin: A Randomized-controlled Trial

Conditions
-----------------
Satisfaction, Consumer Satisfaction

Intervention / Treatment
-----------------
* Other: An in-house manikin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physicians who hold a MD degree Exclusion Criteria: Not want to complete questionnaires No experience in a nasal foreign body removal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: An in-house manikin<br>Participants use an in-house manikin | Other: An in-house manikin<br>* Participants obtain an in-house manikin<br>|
| Sham Comparator: A manikin in market<br>Participants use a manikin from market | Other: An in-house manikin<br>* Participants obtain an in-house manikin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction scores | Satisfaction scores in different manikins using a 5-point Likert scale (1-very unsatisfied to 5- very satisfied). There are a number of scale titles including proper size, proper weight, the ease of use, the ease of cleaning, the ease of maintenance, the flexibility of nasal alae relative to actual anatomy, similarity of the nasal cavity relative to actual anatomy, a well design for teaching, estimated price, participant's confidence if a manikin can upskill medical students to practice in a real patient and overall satisfaction. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
manikin, nasal foreign body
Whole Body Vibration Therapy in Participants With MS Related Balance Deficits

Study Overview
=================
Brief Summary
-----------------
The purpose of this investigation is to determine the effect of Whole Body Vibration Therapy (WBV) on balance in participants with multiple sclerosis (MS) related balance deficits as measured by the NeuroCom Balance Master, the Sapphire IIME EMG Device and the Kurtzke Expanded Disability Status Scale (EDSS) and the Berg Balance Score.

Official Title
-----------------
Whole Body Vibration Therapy in Participants With MS Related Balance Deficits

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Device: Whole Body Vibration machine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Logan student, staff, or faculty or general public with a minimal of 2 year history of diagnosed Multiple Sclerosis (MS) Exclusion Criteria: Visual or vestibular condition that would affect balance Non-Ms related systemic illness that would have an adverse effect on balance Local infection, acute inflammation, injury, tumors or other malignancy, recent wounds, diabetes Any unstable joints of the lower extremity, recent hip and knee joints or fitted hip or knee pins, bolts and/or plates Acute thrombosis Severe migraine, epilepsy Serious cardiovascular disease, wearing a pacemaker Any Spinal manipulation within 48 hours Acute disc herniation, discopathy or spondylolysis Prescription or herbal muscle stimulants, relaxants, etc. that could affect balance Any implanted device or prosthesis or intrauterine IUD type of device Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Whole Body Vibration machine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NeuroCom Balance Master |  |  | 
| SF-EMG Nerve conduction velocity test |  |  | 
| Berg balance score |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MS, Balance, Multiple Sclerosis
Metabolic Phenotyping in Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
After discharge from inpatient treatment, 30-50% of patients with Anorexia Nervosa require re-hospitalization within 4-12 months. So far, high relapse rates are mostly considered as lack of the patient's compliance and motivation to recover. However in studies, psychological relapse predictors explain only a minor part of the variance in relapse risk. Metabolic phenotyping has clinical value to predict weight course in obese patients and we assume that it could also be clinically relevant in patients with AN. We hypothesize that in patients with a dissipative but not with the thrifty phenotype, positive energy balance during refeeding causes an over proportional rise in energy expenditure, counteracts continuous weight gain during inpatient treatment, and increases relapse risk within one year after discharge. Thus we believe that metabolic phenotype as a biological parameter has prognostic value for the disease course in AN.

Official Title
-----------------
Metabolic Phenotyping to Predict Risk of Relapse in Patients With Anorexia Nervosa

Conditions
-----------------
Anorexia Nervosa

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Anorexia Nervosa Between 12 and 18 years of age Written and informed consent of patient and parents Mental ability to understand the concept of the study Inpatient admission to Charité University Clinic with body weight below the 10th BMI-Percentile Exclusion Criteria: Any further disease other than AN with significant influence on body composition and energy metabolism or its assessment

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anorexia Nervosa<br> | |
| Healthy controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse |  | 1 year after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic phenotype |  | Baseline (during inpatient stay) | 
| Biomarkers |  | Baseline (during inpatient stay) |
Health Care Provider Preventiomter Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate health care providers' perceptions, ratings and motivation to adopt a novel and state of the art physical wellness assessment device, the Preventiometer.

Detailed Description
-----------------
The Preventiometer is a physical wellness tool that assesses multiple physical wellness measurements in a 60 +/- 15 minute period of time.

Official Title
-----------------
Health Care Providers Perceptions, Ratings and Motivation to Adopt/Utilize a Novel and State of the Art Physical Wellness Assessment Device (Preventiometer)

Conditions
-----------------
Wellness

Intervention / Treatment
-----------------
* Behavioral: Preventiometer device with wellness coaching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health care providers practicing at Mayo Clinic. Able to speak English and complete surveys. Able to read, understand and sign inform consent. Exclusion Criteria: Unable to sign inform consent. Pregnant women. (As verbalized by participant). Unable to ambulate without assistance. Not currently involved in another formal program or research study involving wellness coaching.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Preventiometer Device<br>The Preventiometer is a physical wellness tool that assesses multiple physical wellness measures in a 60 ± 15 minutes period of time. It is intended to promote population wellness by empowering individuals to act upon the information they receive about their overall health. | Behavioral: Preventiometer device with wellness coaching<br>* Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Likert scale questionnaire on Preventiometer Wellness Assessment | Health care providers perception of the Preventiometer Wellness Device. | 1 day |
Predictive Score for Neonatal Mortality for Women With Premature Rupture of Membranes Between 22 and 28 Weeks of Gestation

Study Overview
=================
Brief Summary
-----------------
Pretern premature rupture of the membranes (PPROM) remains the leading cause of preterm deliveries and neonatal mortality and morbidity. PPROM is defined as rupture of the fetal membranes prior to 37 weeks' gestation. PPROM complicates 2-4% of all pregnancies and accounts for approximately 30 % of preterm births. The etiology of PPROM remains elusive. PPROM is one of the main causes of prematurity and its complications, such as newborn respiratory distress syndrome, neonatal sepsis, necrotizing enterocolitis, intraventricular hemorrhage, perventricular leucomalacia, varying degrees of lung hypoplasia and bronchopulmonary dysplasia. All these factors contribute greatly to an increase in neonatal morbidity and mortality Management of PPROM followed actual guidelines. Conservative management to prolong a pregnancy is a classical approach to treat PPROM before 34 weeks' gestation in association with antibiotic therapy and corticosteroids. Maternal and neonatal data were collected from maternal and newborns medical records.

Official Title
-----------------
Predictive Score for Neonatal Mortality for Women With Premature Rupture of Membranes Between 22 and 28 Weeks of Gestation

Conditions
-----------------
Perinatal Mortality, Premature Rupture of Fetal Membranes

Intervention / Treatment
-----------------
* Other: Validation of a diagnostic test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with PPROM between 22 weeks and 27 weeks and 6 days are eligible for this study Exclusion Criteria: Therapeutic abortion / terminaison of pregnancy Intra uterine demise active labor with cervical dilatation of 3 cm with regular contractions. Triplet pregnancies
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Validation of a diagnostic test|Validation of a diagnostic test|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The purpose was to determine which antepartum criteria were efficient to predict neonatal death, in order to create a predictive prognostic antenatal index of mortality. |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
predictive score
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is a nonrandomized study of pemetrexed plus carboplatin, with the primary objective of determining the efficacy of the combination in tumor reduction, in patients with locally advanced or metastatic breast cancer.

Official Title
-----------------
A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer

Conditions
-----------------
Breast Cancer, Neoplasm Metastasis

Intervention / Treatment
-----------------
* Drug: Pemetrexed
* Drug: Carboplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologic or cytologic diagnosis of locally advanced or metastatic breast cancer No prior chemotherapy for locally advanced or metastatic breast disease. Patient may have received prior adjuvant therapy finished greater than 1 year prior to enrollment. Adequate bone marrow, liver and kidney function RECIST criteria for disease status Exclusion Criteria: Prior treatment with pemetrexed Pregnant or breast feeding Brain Metastasis unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pemetrexed|nan|
|Drug: Carboplatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| antitumor activity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration of response;time to progressive disease;time to treatment failure |  |  |
A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device

Study Overview
=================
Brief Summary
-----------------
A novel dry powder inhaler device will be used to administer mannitol to healthy subjects and subjects with bronchiectasis in single doses higher than previously given.The main objective is to assess tolerability of these doses using the new device.

Official Title
-----------------
A Pilot Study to Investigate the Tolerability of Inhaled Dry Powder Mannitol (IDPM) Administered Via a Novel Dry Powder Inhaler Device in Healthy Individuals and Subjects With Bronchiectasis.

Conditions
-----------------
Healthy, Bronchiectasis

Intervention / Treatment
-----------------
* Drug: dry powder inhaled mannitol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy or bronchiectatic; 18 years and over Exclusion Criteria: uncontrolled asthma, unstable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single<br>single arm, open label, 4 doses tested. | Drug: dry powder inhaled mannitol<br>* single doses of 40 mg, 70 mg and 100 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| tolerability |  | immediately and 10 mins post dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| respiratory symptoms, FEV1 |  | pre-dose, immediately and 10 mins post dose |
Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the expression level of miR-320a are effective as biomarker in evaluating the diagnosis, prognosis and treatment effects of coronary heart disease.

Official Title
-----------------
Evaluation of Plasma Non-coding RNAs (miRNA-320a) as Biomarkers of Diagnosis, Prognosis and Treatment Effects in Coronary Heart Disease

Conditions
-----------------
Coronary Disease

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older; the most recent symptoms of coronary heart disease within 7 days; meet one of the following conditions: A. clinical history of typical ischemic chest pain (more than 5 minutes of persistent chest pain); B. serum cardiac biomarkers positive (TnT/I or creatine kinase peak greater than 99% of URL); C. Electrocardiogram changes of myocardial ischemia. Exclusion Criteria: pregnant women or plan to; participate in any drug clinical trials within 3 months; patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years; serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients); previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix); patients refused to comply with the requirements of this study to complete the research work; according to the researchers, patients can not complete the study or not to comply with the requirements of this study (because of the reasons for the management or other reasons).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with coronary heart disease symptoms<br> | Other: No intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the plasma expression of miR-320a in coronary heart disease patients compared to control patients |  | up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of participants with cardiovascular causes of death |  | up to 24 months | 
| number of participants with non fatal myocardial infarction or stroke |  | up to 24 months | 
| number of participants with re-hospitalization due to cardiovascular causes |  | up to 24 months | 
| number of participants with all causes of mortality |  | up to 24 months | 
| number of participants with myocardial infarction re-exacerbation or re-hospitalization |  | up to 24 months |
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Study Overview
=================
Brief Summary
-----------------
I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Detailed Description
-----------------
Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Official Title
-----------------
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Conditions
-----------------
Neuroblastoma, Pheochromocytoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma Exclusion Criteria: Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 2 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuroblastoma, Pheochromocytoma, MIBG
Availability of Spine Neuronavigation in Africa

Study Overview
=================
Brief Summary
-----------------
In this study, the availability of spine neuronavigation in Africa was evaluated. Access to surgical equipment is an important goal of global surgery and global neurosurgery. The study findings show that there are regional differences in access to spine neuronavigation techniques and highlight that the major barriers to increased prevalence are cost and lack of trained personnel.

Official Title
-----------------
Prevalence of Spine Surgery Navigation Techniques and Availability in Africa: A Cross-sectional Study

Conditions
-----------------
Spine Disease

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neurological and orthopedic surgery residents, fellows and consultants working in Africa. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Survey|Surveyed neurological and orthopedic surgeons|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Availability of neuronavigation | Number of neuronavigation units as discrete unitless counts available at African neurosurgery centers will be collected using an electronic survey | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Access, Africa, computer-assisted surgery, neuronavigation, spine surgery